Holds one active US DMF for glatiramer, filing since 2012. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for glatiramer, filing since 2012. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for glatiramer, filing since 2013. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 14 markets.
Holds one active US DMF for glatiramer, filing since 2014. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 3 markets.
Holds one active US DMF for glatiramer, filing since 2018. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 19 markets.
Holds one active US DMF for glatiramer, filing since 2020. Its 2024 FDA inspection closed as NAI.
Registered with SFDA (Saudi Arabia) for glatiramer. Its GMP is recognised in 14 markets.
Registered with SFDA (Saudi Arabia) for glatiramer. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 15 markets.
Holds one active US DMF for glatiramer, filing since 2012. Its GMP is recognised in 1 market.
The names are listed below. Ask Fred about the filings, inspection history and GMP certificates on record for each manufacturer.
Chat with Fred, your AI analystContract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Ask Fred which manufacturers are on record for glatiramer and what filings they hold.
Chat with Fred, your AI analyst